NCT04987333

Study of Efavaleukin Alfa in Healthy Chinese, Japanese, and Caucasian Participants

A Phase 1, Open-label, Sequential-group, Single-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMG 592 Administered Subcutaneously in Healthy Chinese, Japanese, and Caucasian Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 32 (actual)
• Sponsor: Amgen · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The primary objective of this study is to evaluate the pharmacokinetics (PK) of efavaleukin alfa after single subcutaneous (SC) administration in healthy Chinese, Japanese, and Caucasian participants.

Conditions

• Inflammatory Diseases

Interventions

Type	Name	Description
DRUG	Efavaleukin alfa	Administered as a single dose SC injection.

Timeline

• Start date: 2021-08-09
• Primary completion: 2022-10-03
• Completion: 2022-10-03
• First posted: 2021-08-03
• Last updated: 2024-03-29
• Results posted: 2024-03-29

Locations

1 site across 1 country: United Kingdom

Regulatory

• FDA-regulated drug study